| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 58160-0830-01 | 58160-0830 | Human Papillomavirus Bivalent Vaccine, Recombinant | Cervarix | 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Oct 16, 2009 | Aug 24, 2012 | No Longer Used |
| 58160-0830-52 | 58160-0830 | Human Papillomavirus Bivalent Vaccine, Recombinant | Cervarix | 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jul 25, 2011 | Nov 29, 2016 | No Longer Used |
| 51655-0016-53 | 51655-0016 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 16, 2022 | In Use | |
| 23155-0549-31 | 23155-0549 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jun 15, 2012 | In Use | |
| 51655-0933-54 | 51655-0933 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 11, 2023 | In Use | |
| 00006-4109-02 | 00006-4109 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | In Use | |
| 00378-6868-01 | 00378-6868 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Feb 28, 2011 | Oct 29, 2010 | No Longer Used | |
| 65162-0691-19 | 65162-0691 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 17, 2010 | In Use | |
| 54569-5873-04 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
| 76282-0412-05 | 76282-0412 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 22, 2015 | In Use | |
| 72266-0124-01 | 72266-0124 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Apr 2, 2019 | In Use | |
| 16714-0815-01 | 16714-0815 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 30, 2018 | Aug 31, 2025 | No Longer Used | |
| 53097-0573-60 | 53097-0573 | Dronabinol | MARINOL | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Mar 3, 2021 | In Use | |
| 55390-0054-01 | 55390-0054 | Leucovorin Calcium | Leucovorin Calcium | Ancillary Therapy | Chemoprotective | Antidote | Jun 8, 2000 | Feb 28, 2015 | No Longer Used | ||
| 35356-0853-10 | 35356-0853 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 27, 2007 | In Use | |
| 65293-0373-25 | 65293-0373 | ONDANSETRON HYDROCHLORIDE | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 18, 2009 | Jan 31, 2015 | In Use |
| 00006-4109-06 | 00006-4109 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | May 6, 2011 | In Use |
| 25021-0782-20 | 25021-0782 | ondansetron hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug 30, 2012 | Nov 30, 2021 | No Longer Used |
| 61703-0325-18 | 61703-0325 | Pamidronate Disodium | Pamidronate Disodium | 6.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jul 28, 2003 | In Use | ||
| 63629-4306-09 | 63629-4306 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 20, 2010 | In Use | |
| 80175-0017-01 | 80175-0017 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 11, 2018 | In Use | |
| 00703-7239-39 | 00703-7239 | Ondansetron and Dextrose | Ondansetron and Dextrose | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 22, 2006 | Mar 31, 2011 | No Longer Used | |
| 54569-5873-02 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
| 63629-9166-01 | 63629-9166 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Feb 21, 2022 | In Use | |
| 00006-4109-09 | 00006-4109 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | In Use |
Found 11888 results — Export these results
Home